GeneMatrix Inc (109820) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.027x

Based on the latest financial reports, GeneMatrix Inc (109820) has a cash flow conversion efficiency ratio of 0.027x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩500.19 Million ≈ $338.97K USD) by net assets (₩18.32 Billion ≈ $12.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 109820 equity to assets ratio to measure how much of total assets are equity-financed.

GeneMatrix Inc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how GeneMatrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is GeneMatrix Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.

GeneMatrix Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GeneMatrix Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Silverline Endustri ve Ticaret AS IS:SILVR	-0.012x
Ras Technology Holdings Ltd AU:RTH	0.036x
BIO UV Group PA:ALTUV	0.070x
Israel Op L TA:ISOP	0.000x
L&P Global Berhad KLSE:0268	0.032x
Welcron Company Limited KQ:065950	0.184x
Hubei Geoway Investment Co Ltd SHG:600462	0.893x
Getin Holding SA WAR:GTN	0.068x

Annual Cash Flow Conversion Efficiency for GeneMatrix Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of GeneMatrix Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see GeneMatrix Inc (109820) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩19.23 Billion ≈ $13.03 Million	₩-200.12 Million ≈ $-135.62K	-0.010x	+89.73%
2023-12-31	₩23.15 Billion ≈ $15.69 Million	₩-2.35 Billion ≈ $-1.59 Million	-0.101x	-139.49%
2022-12-31	₩24.19 Billion ≈ $16.39 Million	₩-1.02 Billion ≈ $-693.53K	-0.042x	-140.59%
2021-12-31	₩32.32 Billion ≈ $21.90 Million	₩3.37 Billion ≈ $2.28 Million	0.104x	-22.75%
2020-12-31	₩33.39 Billion ≈ $22.63 Million	₩4.51 Billion ≈ $3.05 Million	0.135x	+190.33%
2019-12-31	₩15.25 Billion ≈ $10.33 Million	₩-2.28 Billion ≈ $-1.54 Million	-0.149x	+40.89%
2018-12-31	₩10.83 Billion ≈ $7.34 Million	₩-2.74 Billion ≈ $-1.86 Million	-0.253x	-57.59%
2017-12-31	₩11.06 Billion ≈ $7.49 Million	₩-1.77 Billion ≈ $-1.20 Million	-0.160x	-436.38%
2016-12-31	₩12.48 Billion ≈ $8.46 Million	₩-373.25 Million ≈ $-252.95K	-0.030x	+49.30%
2015-12-31	₩10.04 Billion ≈ $6.80 Million	₩-591.96 Million ≈ $-401.17K	-0.059x	+49.01%
2014-12-31	₩11.89 Billion ≈ $8.06 Million	₩-1.38 Billion ≈ $-931.91K	-0.116x	--

About GeneMatrix Inc

KQ:109820 Korea Diagnostics & Research

Market Cap

$18.97 Million

₩27.99 Billion KRW

Market Cap Rank

#25249 Global

#1841 in Korea

Share Price

₩1402.00

Change (1 day)

+1.52%

52-Week Range

₩1329.00 - ₩3245.00

All Time High

₩33900.00